Medpace Holdings, Inc. (NASDAQ:MEDP) Position Cut by Wealth Alliance

Wealth Alliance trimmed its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 865 shares of the company’s stock after selling 91 shares during the quarter. Wealth Alliance’s holdings in Medpace were worth $287,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of Medpace by 7.2% during the third quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after purchasing an additional 50,312 shares during the period. Geode Capital Management LLC increased its holdings in shares of Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after purchasing an additional 44,371 shares during the period. Wellington Management Group LLP increased its holdings in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares during the period. American Capital Management Inc. increased its holdings in shares of Medpace by 2.6% during the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after purchasing an additional 9,592 shares during the period. Finally, FMR LLC increased its holdings in shares of Medpace by 11.8% during the third quarter. FMR LLC now owns 231,019 shares of the company’s stock valued at $77,114,000 after purchasing an additional 24,362 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Stock Down 1.2 %

NASDAQ:MEDP opened at $340.78 on Friday. The business’s 50-day moving average price is $343.23 and its 200 day moving average price is $347.46. The firm has a market cap of $10.38 billion, a P/E ratio of 26.98, a PEG ratio of 3.80 and a beta of 1.36. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.